Best Cardiac and Vascular Disorders Companies in North Carolina, United States
The 33 best Cardiac and Vascular Disorders companies in North Carolina, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: AskBio.
Ranked: Best Cardiac and Vascular Disorders companies in North Carolina
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AskBio Developer of AAV technologies for treating genetic and complex disorders | $235M | 73 mo ago | Acquired | 900 | Jude Samulski Co-Founder & CSO | WordPress Block EditorElementorWordPress+25 | 75 patents AAV vector design and delivery for kidney and neurological gene therapies | — |
| 2 | Micell Drug eluting coronary stent | $158M | 109 mo ago | Series D | 2 | — | — | 363 patents Bioabsorbable polymer drug‑eluting coatings for stents and medical devices | — |
| 3 | Infraredx Intravascular imaging pioneers improving coronary artery disease treatment and patient outcomes | $101M | 155 mo ago | Acquired | 59 | — | WordPressMySQLPHP+23 | 147 patents Intravascular imaging catheters with force monitoring and optical blood flow spectroscopy. | — |
| 4 | Adhera Therapeutics Developer of small molecule based therapeutics for treatment of hypertension | $86M | 80 mo ago | Deadpooled | 20 | — | — | — | — |
| 5 | Bardy Diagnostics Medical technology company providing solutions for healthcare providers, caregivers, and patients | $83M | 80 mo ago | Acquired | 229 | — | WordPressMySQLMariaDB+27 | 380 patents Wearable ECG patch technology with adhesive, remote streaming, and inductive recharging. | — |
| 6 | nContact Epicardial ablation devices | $68M | 143 mo ago | Acqui-Hired | 14 | Sidney Fleischman Co-Founder | — | — | — |
| 7 | Cardioxyl Pharmaceuticals Clinical stage biopharmaceutical company | $66M | 167 mo ago | Acquired | 11 | Chris Boerner Board Chair and Chief Executive Officer | — | 308 patents Nitroxyl donor compounds for cardiovascular therapeutic applications | — |
| 8 | Contego Medical Provider of vascular stenting with embolic protection for both coronary and peripheral vasculature | $66M | 42 mo ago | Series D | 33 | — | — | — | — |
| 9 | Aldagen Regenerative cell therapies for vascular disorders | $62M | 177 mo ago | Acquired | 18 | Tom Amick CEO & President | — | 16 patents Enhancing stem cell transplantation using ALDHbr cell populations for improved engraftment | — |
| 10 | nContact Surgical Cardiac ablation technology | $51M | 163 mo ago | Acquired | 14 | John Funkhouser CEO & President | — | 81 patents Surgical devices for tissue coagulation and atrial remodeling prevention | — |
| 11 | InnerPulse Vascular implant for the correction of arrhythmia | $50M | 237 mo ago | Deadpooled | — | Richard Stack Co-Founder | — | 19 patents Patents concentrated in health & consumer products | — |
| 12 | Valencell Developer of based medical sensors for monitoring body vitals | $38M | 81 mo ago | Series E | 34 | Steven Leboeuf President & Co-Founder | Tailwind CSSVue.jsAstro+13 | 418 patents Wearable photoplethysmography sensors for real-time health metrics estimation | — |
| 13 | Sapheon Closure system for treatment of venous reflux disease | $36M | 155 mo ago | Acquired | 20 | — | — | 21 patents Venous occlusion/treatment devices and microwave sterilization of medical adhesives | — |
| 14 | Precise Bio Developer of integrated 3D printing and tissue-engineering platform | $19M | 33 mo ago | Series B | 6 | Shay Soker Co-Founder & CSO | WordPressMySQLPHP+23 | — | — |
| 15 | NuPulseCV Transforming chronic heart failure treatment with minimally invasive cardiac assist devices | $14M | 64 mo ago | Series A | 23 23 → 20 (-13%) | Douglas Altschuler Founder & CEO | — | 81 patents Cardiovascular mechanical support devices and real-time cardiac rhythm monitoring technologies | — |
| 16 | Cerulean Scientific Developer of an implantable medical devices for vascular patients | $14M | 16 mo ago | Funding Raised | — | Lora Allemeier CEO | — | — | — |
| 17 | HeartIT Medical image viewing, management and sharing platforms | $13M | 157 mo ago | Acqui-Hired | 17 | — | — | — | — |
| 18 | SonoVol Ultrasonic device for tissue and vasculature imaging in preclinical setting | $12M | 56 mo ago | Acquired | 12 | Ryan Gessner President And Interim Chief Executive Officer | — | 4 patents Preclinical ultrasound imaging systems and noninvasive bioengineered organ assessment technologies. | — |
| 19 | Sonovascular eveloper of a medical device to treat arterial and venous diseases | $8M | 8 mo ago | Series A | 8 | Daniel Estay Founder & CEO | WebflowjQueryHSTS+5 | 7 patents Intravascular ultrasound catheter systems for medical imaging and therapeutic guidance | — |
| 20 | NanoCor Therapeutics Developer of targeted drug delivery system for the treatment of CHF | $8M | 229 mo ago | Deadpooled | — | Sheila Mikhail CEO | — | — | — |
| 21 | Vascular BioSciences Vascular BioSciences: Pioneering targeted therapies, interventional devices, and molecular diagnostics | $8M | 18 mo ago | Funding Raised | 24 | David Mann CEO & Chairman | — | — | — |
| 22 | InnAVasc Innovative medical device company focused on safer hemodialysis access solutions | $3M | 59 mo ago | Acquired | 8 | — | — | — | — |
| 23 | APIE Therapeutics Developer of drugs for treating pulmonary, cardiovascular, and metabolic diseases | $802K | 37 mo ago | Funding Raised | 4 | — | — | — | — |
| 24 | CardioDiagnostics Remote monitoring and transmission of vital cardiac information | $540K | 85 mo ago | Seed | 35 | — | Windows ServerMicrosoft ASP.NETBootstrap+16 | — | — |
| 25 | Sapere Bio Diagnostic company that develops non-invasive biomarker tests to measure cellular aging and predict the risk… | $500K | 28 mo ago | Seed | 5 | Norman Sharpless Co-Founder | — | — | — |
Top 12 Cardiac and Vascular Disorders companies in North Carolina
#1
Series A · Chapel Hill, North Carolina · founded 2017 · 8 employees$8.3Mraised▾
Developer of a medical device to treat arterial and venous diseases. It offers multi-mechanism thrombectomy system for the endovascular treatment of diseases which include deep vein thrombosis, pulmonary embolism, peripheral artery occlusion, and acute ischemic stroke.
- Feb 2026Series A$6M
- Jul 2023Seed—
- Jan 2023Conventional Debt$2.2M
- Aug 2020Grant (prize money)$150K
#2
Funding Raised · Durham, North Carolina · founded 2023$14.1Mraised▾
Developer of an implantable medical devices for vascular patients. It offers a device with omniphobic coatings to resist pathogen colonization and thrombosis with technology that increases survival time and improvedclinical outcomes.
- Jun 2025Grant (prize money)$1.7M
- Mar 2025Grant (prize money)$2.9M
- Jan 2025Grant (prize money)$1.7M
- Sep 2024Grant (prize money)$297.7K
#3
Funding Raised · Durham, North Carolina · founded 1990 · 24 employees$7.9Mraised▾
Vascular BioSciences: Pioneering targeted therapies, interventional devices, and molecular diagnostics. The company develops innovative solutions for serious vascular diseases. It focuses on targeted therapeutics using CAR peptide technology for pulmonary hypertension, sepsis, and other diseases, enhancing drug efficacy and reducing side effects. The company's interventional products include the endoarterial biopsy catheter, enabling minimally invasive diagnosis and monitoring of vascular conditions. Molecular diagnostics provide comprehensive vascular disease profiles through analysis of biopsy samples. The company aims to improve patient outcomes through advanced medical technologies, offering products and services that address critical needs in vascular health. The company's mission is to enhance and prolong human life by developing disease solutions.
- Apr 2025Grant (prize money)$2.6M
- Sep 2021Grant (prize money)$2.6M
- Aug 2017Grant (prize money)$2.3M
- Aug 2011Grant (prize money)$220.4K
#4
Series D · Raleigh, North Carolina · founded 2005 · 33 employees$66Mraised▾
Provider of vascular stenting with embolic protection for both coronary and peripheral vasculature. The company's product offering includes Corguard - coronary stent system with integrated embolic protection; Vanguard - peripheral dilation balloon with integrated embolic protection; Paladin - carotid post-dilation balloon with integrated embolic protection.
- Apr 2023Series D$23M
- Apr 2022Series D$15.1M
- Jun 2020Series C—
- Jan 2020Series C$22.3M
#5
Acquired · Durham, North Carolina · founded 2001 · 900 employees$235Mraised▾
Developer of AAV technologies for treating genetic and complex disorders. The company is engaged in the development and delivery of novel protein and cellular-based therapies through the design of proprietary recombinant Adeno associated virus (AAV) Biological Nano Particles (BNP). The gene delivery technology platform provides unsurpassed transduction efficiency, "ramp-up" expression capabilities, with tissue targeting and de-targeting properties. Its product pipeline includes drugs to treat muscular dystrophy, hemophilia B, congestive heart failure, epilepsy, retinitis pigmentosa, and osteoporosis.
- Sep 2020Grant (prize money)$2.7M
- Apr 2019PE$235M
- Aug 2014Grant (prize money)$270K
- Sep 2010Grant (prize money)$321K
#6
Series B · Winston-salem, North Carolina · founded 2015 · 6 employees$19Mraised▾
Developer of integrated 3D printing and tissue-engineering platform. The platform allows the production of repeatable bio-fabricated organs from the patient's own cells for cardiology, orthopedics, dermatology, and more. The company's lead product is 3D cardiac tissue “patch” for post-myocardial infarction (MI) implant to retrieve cardiac muscle viability and functionality.
- Jan 2024Series B$12M
- Jul 2022Seed—
- Feb 2022Conventional Debt$15.5M
- Series A$7M
#7
Series D · Raleigh, North Carolina · founded 1995 · 2 employees$157.5Mraised▾
Micell Technologies has developed a drug delivery technology for coronary artery disease based on surface and polymer modification technologies. The company's lead product candidate, MiStent is a Sirolimus Eluting Absorbable Polymer Coronary Stent System. It is also developing a drug coated balloon and a fully absorbable stent for vascular interventions. MiStent has received CE Mark.
- Sep 2017Series D$62M
- Nov 2016Series C$25.8M
- Nov 2016Conventional Debt—
- Dec 2009Series C$300.1K
#8
Deadpooled · Durham, North Carolina · founded 1983 · 20 employees$85.9Mraised▾
Adhera Therapeutics has developed small molecule-based therapeutics for the treatment of hypertension. The company's lead product candidate Prestalia is a fixed-dose combination (FDC) of perindopril arginine and amlodipine besylate. It contains perindopril arginine, an angiotensin-converting enzyme inhibitor, and amlodipine, a dihydropyridine calcium channel blocker, used for lowering blood pressure and thus for the treatment of hypertension. The product is FDA approved and is already marketed.
- Feb 2020Post IPO$499.9K
- Jul 2019Conventional Debt$3.2M
- Jul 2018Post IPO$1.5M
- Apr 2018Post IPO$11.7M
#9
Acquired · Burlington, North Carolina · founded 1998 · 59 employees$101Mraised▾
Intravascular imaging pioneers improving coronary artery disease treatment and patient outcomes. They are dedicated to conquering vascular disease through innovative solutions. They develop and provide high-resolution intravascular imaging platforms that combine structural views with plaque compositional analysis, offering treatment insights. Their products include HD-IVUS and IVUS+NIRS systems, along with essential accessories. They focus on identifying unstable lipid-core plaques to prevent major adverse cardiac events. They are involved in clinical research, conducting studies to evaluate the safety and effectiveness of their technologies. They aim to optimize the treatment of polyvascular disease patients. They provide educational resources, including webinar sessions and an IVUS app. They are committed to advancing clinical research and innovation in cardiovascular imaging and diagnostics. They are a medical device company focused on improving lives through innovative medical products.
- Nov 2013Conventional Debt$20M
- Aug 2013Series C$25M
- Dec 2011Conventional Debt$10M
- Jun 2011Series C$24.2M
#10
Acquired · Charlotte, North Carolina · founded 2013 · 229 employees$83.4Mraised▾
Medical technology company providing solutions for healthcare providers, caregivers, and patients. The company focuses on developing and manufacturing a wide range of medical devices and equipment. These include diagnostic cardiology, patient monitoring systems, healthcare furniture, and surgical solutions. The company offers products and services across various healthcare settings, such as hospitals, surgical centers, and home healthcare. The company aims to improve patient outcomes and enhance the efficiency of healthcare delivery through innovative medical technologies. The company provides solutions for vital signs monitoring, safe patient handling, respiratory therapy, and surgical workflow. The company also offers services like remote management, repair, and customer experience centers. The company's products incorporate advanced technologies and connectivity features.
- Feb 2020Series B$12.5M
- Jan 2019Series B$35.5M
- Jul 2018Series B—
- Jun 2018Series B$35.4M
#11
Acqui-Hired · Morrisville, North Carolina · founded 2005 · 14 employees$67.7Mraised▾
nContant has developed the EPi-Sense and Numeris Coagulation System and VisiTrax epicardial ablation device for treatment of atrial fibrillation. The EPi-Sense and Numeris Coagulation System with VisiTrax have CE Mark Approval in Europe for the coagulation of cardiac tissue for the treatment of atrial fibrillation and atrial flutter. It integrates suction, perfusion, and radiofrequency energy to ensure cardiac tissue contact and energy transmission to create linear lesions on a beating heart. Numeris with VisiTrax is also indicated for endoscopic coagulation of cardiac tissue in the United States.
- Nov 2014Series D$20M
- Mar 2013Series D$6.7M
- Jan 2012Conventional Debt$433.8K
- Nov 2010Series C$16.2M
#12
Series E · Raleigh, North Carolina · founded 2006 · 34 employees$37.6Mraised▾
Developer of AI-based medical devices for monitoring body vitals. It offers the technology for monitoring blood pressure, heart rate, VO2 max, step count, and respiration rate. The company offers PPG sensors that can calibrate multiple health vitals of the body for the wearable and hearable industry.
- Jan 2020Series E—
- Jun 2018Series E$10.5M
- Mar 2016Series D$11M
- Sep 2015Series C$2.6M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Cardiac and Vascular Disorders coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.